On May 21, Moody's maintained the issuer rating of Kantar Baa2, and the outlook was adjusted from stable to negative due to uncertainty brought about by the proposed US bill.
Moody's said that the confirmation of Pharmaceutical Kangde Baa2 issuer rating reflects the company's leading market position as a contract research institution with a full-service new drug development and manufacturing service platform in China, its low debt leverage and excellent liquidity.